Effects of Substance Misuse on Reward-processing in Patients with Attention-deficit/hyperactivity Disorder

Overview

Journal Neuropsychopharmacology

Date 2020 Nov 13

PMID 33184474

Citations 4

Authors

Maria Paraskevopoulou

Daan van Rooij

Albert Batalla

Roselyne Chauvin

Maartje Luijten

Aart H Schene

Jan K Buitelaar

Arnt F A Schellekens

Affiliations

Soon will be listed here.

Abstract

Attention-Deficit/Hyperactivity Disorder (ADHD) and Substance Use Disorder (SUD) often co-occur and are associated with treatment resistance. Both disorders are characterized by similar reward-processing deficits with decreased striatal responses to reward anticipation, though literature is inconsistent. It is unclear whether substance misuse exaggerates reward-processing deficits observed in ADHD. The aim of this study was to examine substance misuse effects on reward-processing in ADHD. Functional MRI data in a Monetary Incentive Delay (MID) task from a multi-site study were compared across ADHD groups with and without substance misuse (ADHD + SM and ADHD-only, respectively) and healthy controls (n = 40/group, 74 males and 46 females, aged 13.7-25.9 years). Substance misuse was defined as misuse of alcohol, nicotine, or drugs. Groups were matched with presence/absence of parental SUD to avoid interference with SUD trait effects. Compared to ADHD-only and controls, ADHD + SM showed hyperactivation in putamen during reward anticipation. Compared to controls, the ADHD groups showed hypoactivation in motor/sensory cortices and hyperactivation in frontal pole and OFC during reward outcome. ADHD + SM also showed hyperactivation in frontal pole during neutral outcome. Moreover, ADHD + SM patients showed higher callous-unemotional (CU) traits that were positively correlated with putamen responses to reward anticipation. Our results show distinct condition-independent neural activation profile for ADHD + SM compared to ADHD-only and controls. Effects of comorbid substance misuse and variability of its prevalence across ADHD studies might have contributed to inconsistencies in ADHD literature. Contrasted with findings for reward-processing in SUD literature, results potentially suggest distinct underlying mechanisms for SUD subgroups with different characteristics, like antisocial/psychopathic traits.

Citing Articles

Attention-Deficit Hyperactivity Disorder and Therapeutic Cannabis Use Motives.

Hernandez M, Levin F Psychiatr Clin North Am. 2022; 45(3):503-514.

PMID: 36055735 PMC: 11032069. DOI: 10.1016/j.psc.2022.05.010.

Neurobehavioral maturation of motor response inhibition in adolescence - A narrative review.

Weiss H, Luciana M Neurosci Biobehav Rev. 2022; 137:104646.

PMID: 35367223 PMC: 9119966. DOI: 10.1016/j.neubiorev.2022.104646.

Altered single-subject gray matter structural networks in drug-naïve attention deficit hyperactivity disorder children.

Chen Y, Lei D, Cao H, Niu R, Chen F, Chen L Hum Brain Mapp. 2021; 43(4):1256-1264.

PMID: 34797010 PMC: 8837581. DOI: 10.1002/hbm.25718.

Effects of substance misuse on inhibitory control in patients with attention-deficit/hyperactivity disorder.

Paraskevopoulou M, van Rooij D, Schene A, Chauvin R, Buitelaar J, Schellekens A Addict Biol. 2021; 27(1):e13063.

PMID: 34101312 PMC: 9285045. DOI: 10.1111/adb.13063.

References

Faraone S, Biederman J, Mick E . The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med. 2006; 36(2):159-65. DOI: 10.1017/S003329170500471X. View

Polanczyk G, Rohde L . Epidemiology of attention-deficit/hyperactivity disorder across the lifespan. Curr Opin Psychiatry. 2007; 20(4):386-92. DOI: 10.1097/YCO.0b013e3281568d7a. View

Molina B, Pelham Jr W . Attention-deficit/hyperactivity disorder and risk of substance use disorder: developmental considerations, potential pathways, and opportunities for research. Annu Rev Clin Psychol. 2014; 10:607-39. PMC: 4097844. DOI: 10.1146/annurev-clinpsy-032813-153722. View

Lee S, Humphreys K, Flory K, Liu R, Glass K . Prospective association of childhood attention-deficit/hyperactivity disorder (ADHD) and substance use and abuse/dependence: a meta-analytic review. Clin Psychol Rev. 2011; 31(3):328-41. PMC: 3180912. DOI: 10.1016/j.cpr.2011.01.006. View

Biederman J, Wilens T, Mick E, Milberger S, Spencer T, Faraone S . Psychoactive substance use disorders in adults with attention deficit hyperactivity disorder (ADHD): effects of ADHD and psychiatric comorbidity. Am J Psychiatry. 1995; 152(11):1652-8. DOI: 10.1176/ajp.152.11.1652. View

Sizoo B, van den Brink W, Koeter M, Gorissen van Eenige M, van Wijngaarden-Cremers P, Van der Gaag R . Treatment seeking adults with autism or ADHD and co-morbid substance use disorder: prevalence, risk factors and functional disability. Drug Alcohol Depend. 2009; 107(1):44-50. DOI: 10.1016/j.drugalcdep.2009.09.003. View

Wilens T . Impact of ADHD and its treatment on substance abuse in adults. J Clin Psychiatry. 2004; 65 Suppl 3:38-45. View

Castells X, Ramos-Quiroga J, Rigau D, Bosch R, Nogueira M, Vidal X . Efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder: a meta-regression analysis. CNS Drugs. 2011; 25(2):157-69. DOI: 10.2165/11539440-000000000-00000. View

Faraone S, Asherson P, Banaschewski T, Biederman J, Buitelaar J, Ramos-Quiroga J . Attention-deficit/hyperactivity disorder. Nat Rev Dis Primers. 2016; 1:15020. DOI: 10.1038/nrdp.2015.20. View

10.

Coffey S, Gudleski G, Saladin M, Brady K . Impulsivity and rapid discounting of delayed hypothetical rewards in cocaine-dependent individuals. Exp Clin Psychopharmacol. 2003; 11(1):18-25. DOI: 10.1037//1064-1297.11.1.18. View

11.

Adisetiyo V, Gray K . Neuroimaging the neural correlates of increased risk for substance use disorders in attention-deficit/hyperactivity disorder-A systematic review. Am J Addict. 2017; 26(2):99-111. DOI: 10.1111/ajad.12500. View

12.

Haber S, Knutson B . The reward circuit: linking primate anatomy and human imaging. Neuropsychopharmacology. 2009; 35(1):4-26. PMC: 3055449. DOI: 10.1038/npp.2009.129. View

13.

Galvan A . Adolescent development of the reward system. Front Hum Neurosci. 2010; 4:6. PMC: 2826184. DOI: 10.3389/neuro.09.006.2010. View

14.

Shaw P, De Rossi P, Watson B, Wharton A, Greenstein D, Raznahan A . Mapping the development of the basal ganglia in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2014; 53(7):780-9.e11. PMC: 10461726. DOI: 10.1016/j.jaac.2014.05.003. View

15.

Plichta M, Scheres A . Ventral-striatal responsiveness during reward anticipation in ADHD and its relation to trait impulsivity in the healthy population: a meta-analytic review of the fMRI literature. Neurosci Biobehav Rev. 2013; 38:125-34. PMC: 3989497. DOI: 10.1016/j.neubiorev.2013.07.012. View

16.

Paloyelis Y, Mehta M, Faraone S, Asherson P, Kuntsi J . Striatal sensitivity during reward processing in attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2012; 51(7):722-732.e9. PMC: 3763946. DOI: 10.1016/j.jaac.2012.05.006. View

17.

Scheres A, Milham M, Knutson B, Castellanos F . Ventral striatal hyporesponsiveness during reward anticipation in attention-deficit/hyperactivity disorder. Biol Psychiatry. 2006; 61(5):720-4. DOI: 10.1016/j.biopsych.2006.04.042. View

18.

Luijten M, Schellekens A, Kuhn S, Machielse M, Sescousse G . Disruption of Reward Processing in Addiction : An Image-Based Meta-analysis of Functional Magnetic Resonance Imaging Studies. JAMA Psychiatry. 2017; 74(4):387-398. DOI: 10.1001/jamapsychiatry.2016.3084. View

19.

Schouw M, de Ruiter M, Kaag A, van den Brink W, Lindauer R, Reneman L . Dopaminergic dysfunction in abstinent dexamphetamine users: results from a pharmacological fMRI study using a reward anticipation task and a methylphenidate challenge. Drug Alcohol Depend. 2012; 130(1-3):52-60. DOI: 10.1016/j.drugalcdep.2012.10.010. View

20.

Cope L, Martz M, Hardee J, Zucker R, Heitzeg M . Reward activation in childhood predicts adolescent substance use initiation in a high-risk sample. Drug Alcohol Depend. 2018; 194:318-325. PMC: 6540995. DOI: 10.1016/j.drugalcdep.2018.11.003. View